AstraZeneca Pharma tanks on reverse turnaround in Q3

AstraZeneca Pharma India tanked 9.91% to Rs 1,030 at 11:20 IST on BSE after the company reported net loss of Rs 10.35 crore in Q3 December 2017 compared with net profit of Rs 16.21 crore in Q3 December 2016.

Net sales dropped 14.5% to Rs 128.54 crore in Q3 December 2017 over Q3 December 2016.

The result was announced after market hours yesterday, 5 February 2018.

Meanwhile, the S&P BSE Sensex was down 982.41 points, or 2.83% to 33,783.56. The S&P BSE Small-Cap index was down 662.15 points, or 3.72% to 17,119.64, underperforming the Sensex.

On the BSE, 1,940 shares were traded in the counter so far, compared with average daily volumes of 4,160 shares in the past one quarter. The stock had hit a high of Rs 1,089 and a low of Rs 1,022.50 so far during the day. The stock had hit a 52-week high of Rs 1,278 on 7 November 2017. The stock had hit a 52-week low of Rs 882.55 on 22 August 2017.

The stock lost 7.9% over the past one month till 5 February 2018, underperforming the Sensex's 1.77% rise. The scrip however, outperformed the market in past one quarter, gaining 7.12% as against Sensex's 3.18% rise. The scrip, however, underperformed the market in past one year, advancing 19.67% as against Sensex's 23.08% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma India is a subsidiary of AstraZeneca Plc, UK. It covers manufacturing, sales and marketing activities of the company in India. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular and & metabolic diseases, oncology and respiratory.

Powered by Capital Market - Live News